Table 1.
Clinical Characteristics and Preprocedural Antiplatelet/anticoagulant Agents (Normal Platelet Group vs. Thrombocytopenia Group).
| Normal platelet | Thrombocytopenia | p | |
|---|---|---|---|
| n=1,009 | n=226 | ||
| Age (mean years±SD) | 72±10 | 74±9 | 0.024 |
| Male (%) | 741 (73.4) | 169 (74.8) | 0.679 |
| Platelets (×103/μL) | 222±55 | 122±23 | <0.001 |
| BMI (kg/m2) | 23.4±3.7 | 22.6±3.5 | 0.001 |
| Hypertension (%) | 766 (75.9) | 175 (77.4) | 0.628 |
| Diabetes mellitus (%) | 442 (43.8) | 120 (53.1) | 0.011 |
| Dyslipidemia (%) | 671 (66.5) | 137 (60.6) | 0.093 |
| Current smoking (%) | 163 (16.2) | 27 (11.9) | 0.113 |
| Hemodialysis (%) | 103 (10.2) | 73 (32.3) | <0.001 |
| Hb (g/dL) | 12.6±1.8 | 11.6±1.7 | <0.001 |
| PCI indication | |||
| Stable AP (%) | 507 (50.2) | 85 (37.6) | 0.003 |
| SMI (%) | 424 (42.0) | 118 (52.2) | |
| ACS (%) | 78 (7.7) | 23 (10.2) | |
| Preprocedural medication | |||
| Aspirin (%) | 875 (86.7) | 190 (84.1) | 0.296 |
| Thienopiridine (%) | 805 (79.8) | 165 (73.0) | 0.025 |
| DAPT (%) | 754 (74.7) | 155 (68.6) | 0.058 |
| Anticoagulant (%) | 86 (8.5) | 32 (14.2) | 0.009 |
| Triple therapy (%) | 58 (5.7) | 20 (8.8) | 0.083 |
BMI: body mass index, Hb: hemoglobin, PCI: percutaneous coronary intervention, AP: angina pectoris, SMI: silent myocardial ischemia, ACS: acute coronary syndrome, DAPT: dual antiplatelet therapy